Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

483
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
483
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Coronary Artery Disease V: Surgical Management01:27

Coronary Artery Disease V: Surgical Management

3
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
3
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

581
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
581
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

2
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
2
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

3
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
3

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term mavacamten exposure reduces force and sarcomere density in a hiPSC model of hypertrophic cardiomyopathy.

Cardiovascular research·2026
Same author

Obesity and Pharmacokinetic Variability: Implications for Cardiovascular Therapeutics.

European cardiology·2026
Same author

C1qa□ muscularis macrophages maintain enteric synaptic homeostasis to regulate gastrointestinal motility.

bioRxiv : the preprint server for biology·2026
Same author

Antidotes for Anticoagulation Reversal.

The New England journal of medicine·2026
Same author

A TRIP-nano killer silencing the pain pacemakers.

The Journal of physiology·2026
Same author

Innovation and constraints in cardiovascular pharmacotherapy.

European heart journal. Cardiovascular pharmacotherapy·2026

Related Experiment Video

Updated: Jun 11, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

801

Ticagrelor and Statins: Dangerous Liaisons?

Bianca Rocca1,2, Elisabetta Bigagli3, Elisabetta Cerbai4

  • 1Department of Safety and Bioethics, Catholic University, Largo F. Vito 1, Rome, Italy.

Cardiovascular Drugs and Therapy
|September 30, 2024
PubMed
Summary

Ticagrelor can inhibit breast cancer resistance protein (BCRP), increasing statin levels and the risk of rhabdomyolysis. Cardiovascular patients on ticagrelor and statins require careful monitoring for this drug-drug interaction.

Keywords:
Cytochrome P450Drug interactionsRhabdomyolysisStatinsTicagrelorTransporters

More Related Videos

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Related Experiment Videos

Last Updated: Jun 11, 2025

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

801
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

4.8K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.6K

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Drug Interactions

Background:

  • Polypharmacy is common in cardiovascular patients, increasing the risk of drug-drug interactions (DDIs).
  • Anti-thrombotic drugs and statins are frequently co-prescribed in this population.
  • DDIs involving statins can lead to severe adverse events like rhabdomyolysis.

Purpose of the Study:

  • To investigate the mechanism of DDIs between ticagrelor and statins.
  • To identify the role of breast cancer resistance protein (BCRP) in ticagrelor-statin interactions.
  • To assess the potential risk of rhabdomyolysis associated with this DDI.

Main Methods:

  • In vitro studies to assess BCRP inhibition by ticagrelor.
  • Pharmacokinetic trials evaluating drug concentrations.
  • In silico drug modeling to validate interaction mechanisms.

Main Results:

  • Ticagrelor was identified as an inhibitor of the BCRP transporter.
  • This inhibition by ticagrelor increases the concentration of statins that are BCRP substrates.
  • Observational studies suggest an increased risk of rhabdomyolysis with ticagrelor and certain statins.

Conclusions:

  • Ticagrelor's inhibition of BCRP is a validated mechanism contributing to DDIs with statins.
  • This interaction may lead to increased statin concentrations and a higher risk of rhabdomyolysis.
  • Caution and further investigation are warranted when co-prescribing ticagrelor with susceptible statins.